Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show

MedPage Today) — Venetoclax (Venclexta) combined with a hypomethylating agent (HMA) — the standard of care for older patients with acute myeloid leukemia (AML) — appeared to be safe and effective in patients in their 80s and 90s, a retrospective…
Read More